# US 2024/0174755 A1 · Platelet derived growth factor receptor (pdgfr) antibodies, conjugates, compositions, and uses thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0174755 A1
- Document ID: US20240174755A1
- Status: Published application
- Kind: A1
- Application number: 17/760,252
- Filed: 2021-02-05
- Published: 2024-05-30
- Earliest claimed: 2020-02-07
- Assignees: Biorion Technologies B.V.
- Applicants: Biorion Technologies B.V.
- Inventors: Hermannus STEEN; Gustaaf Johan Marie VAN SCHARRENBURG
- Web page: https://patentgrep.com/patent/US20240174755A1

## CPC

- C07K 16/2863: {against receptors for growth factors, growth regulators}
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61K 47/6849: {the antibody targeting a receptor, a cell surface antigen or a cell surface determinant}
- A61K 49/0002: {General or multifunctional contrast agents, e.g. chelated agents}
- A61K 51/103: {against receptors for growth factors or receptors for growth regulators}
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 35/00: Antineoplastic agents
- C07K 2317/31: multispecific
- C07K 2317/33: Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
- C07K 2317/35: Valency
- C07K 2317/569: Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
- C07K 2317/92: Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C07K 2319/00: Fusion polypeptide
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The invention relates to antibodies against the Platelet Derived Growth Factor Receptor beta (PDGFR β), and the use thereof in diagnostic and/or therapeutic applications. In particular, it provides a (VHH) antibody that specifically binds PDGFR β with an apparent binding affinity of less than 10 nM, preferably less than 5 nM, and which does not activate PDGFR β. Also provided are PDGFR β antibodies and conjugates thereof, and their application in the targeted delivery of a diagnostic agent, a therapeutic agent or a combination thereof to a tissue in a subject, in particular to fibrotic tissue comprising activated myofibroblasts.

## Claims

### Claim 1

An antibody that specifically binds to the Platelet-derived growth factor receptor beta (PDGFR β) with a binding affinity of less than 10 nM.

### Claim 2 (depends on 1)

The PDGFR β antibody according to claim 1, which binds to the dimeric form of the PDGFR β with a binding affinity of less than 10 nM.

### Claim 3 (depends on 1)

The PDGFR β antibody according to claim 1, which binds to human PDGFR β with a binding affinity of less than 10 nM.

### Claim 4 (depends on 1)

The PDGFR antibody according to claim 1, which is a single heavy chain variable domain (VHH) antibody.

### Claim 5 (depends on 1)

A PDGFR β antibody according to claim 1, comprising
a heavy chain CDR1, CDR2 and CDR3 sequence as defined by ID NO: 1, 5 and 9, respectively, or sequences showing at least 90% identity thereto;
heavy chain CDR1, CDR2 and CDR3 sequence as defined by ID NO: 2, 6 and 10, respectively, or sequences showing at least 90% identity thereto;
a heavy chain CDR1, CDR2 and CDR3 sequence as defined by ID NO: 3, 7 and 11, respectively, or sequences showing at least 90% identity thereto; or
a heavy chain CDR1, CDR2 and CDR3 sequence as defined by ID NO: 4, 8 and 12, respectively, or sequences showing at least 90% identity thereto.

### Claim 6 (depends on 5)

The PDGFR β antibody of claim 5, comprising a heavy chain variable region comprising a sequence as set forth in SEQ ID NO: 25-32, or a variant or a derivative thereof.

### Claim 7 (depends on 6)

The PDGFR β antibody according to claim 6, comprising a heavy chain variable region comprising a sequence as set forth in SEQ ID NO: 25 or 26.

### Claim 8 (depends on 1)

The PDGFR β antibody of claim 1, comprising a peptide-tag allowing for purification, a tag allowing for site-specific antibody conjugation, and/or a tag allowing for targeting and/or retention in an organ of interest.

### Claim 9 (depends on 1)

The PDGFR β antibody according to claim 1, further comprising a detectable label, a (radio)therapeutic agent, a carrier, or any combination thereof.

### Claim 10 (depends on 9)

The PDGFR β antibody according to claim 9, wherein the detectable label is an in vivo detectable label which can be detected in vivo using nuclear magnetic resonance NMR imaging, near-infrared imaging, positron emission tomography (PET), scintigraphic imaging, ultrasound, or fluorescence analysis.

### Claim 11 (depends on 9)

The PDGFR β antibody according to claim 9, wherein the therapeutic agent is selected from the group consisting of a radionuclide, a cytotoxin, and a chemotherapeutic agent.

### Claim 12 (depends on 9)

The PDGFR β antibody according to claim 9, wherein the carrier is selected from the group consisting of a liposome, a polymersome, a nanoparticle and a microcapsule.

### Claim 13 (depends on 1)

A bivalent bispecific, bivalent biparatopic or multispecific binding compound comprising a PDGFR β antibody according to claim 1.

### Claim 14 (depends on 1)

A nucleic acid encoding an antibody of claim 1.

### Claim 15 (depends on 1)

A method for producing the antibody of claim 1, the method comprising expressing the nucleic acid in a relevant host cell and recovering the thus produced antibody from the cell, optionally further comprising providing the antibody with a detectable label, a therapeutic agent, a carrier, or any combination thereof.

### Claim 16 (depends on 1)

A therapeutic composition, a diagnostic composition, or a combination thereof, comprising one or more antibodies according to claim 1.

### Claim 17 (depends on 1)

The PDGFR β antibody according to claim 1, for use as targeting agent, diagnostic agent, therapeutic agent or any combination thereof.

### Claim 18 (depends on 1)

The PDGFR β antibody of claim 1 for use in a method of diagnosing and/or treatment of a PDGF-mediated disease or medical condition in a mammal.

### Claim 19 (depends on 18)

The PDGFR β antibody for use according to claim 18, wherein said PDGF-mediated disease or medical condition is cancer, restenosis, fibrosis, angiogenesis, renal disease or cardiovascular disease.

### Claim 20 (depends on 18)

The PDGFR β antibody for use according to claim 18, wherein the method for treatment further comprises the administration of at least one further (chemo/(radio)therapeutic agent.

### Claim 21 (depends on 1)

A method for diagnosing and/or treating of a PDGF-mediated disease or medical condition in a mammalian subject comprising administering to the subject a PDGFR β antibody of claim 1.

### Claim 22 (depends on 21)

The method according to claim 21, wherein said PDGF-mediated disease or medical condition is cancer, restenosis, fibrosis, angiogenesis, pulmonary disease, renal disease or cardiovascular disease.

### Claim 23 (depends on 21)

The method of treatment according to claim 21, wherein the treatment further comprises the administration of at least one further (chemo)therapeutic agent.
